… Tamoxifen use was reported more often by BRCA2 mutation carriers than by BRCA1 …
We have shown that tamoxifen is effective in both BRCA1 and BRCA2 mutation carriers. …

… This study provides evidence that tamoxifen use is associated with a reduction in CBC
risk for BRCA1 and BRCA2 mutation carriers. Further follow-up of these cohorts will provide …

… of contralateral breast cancer in carriers of BRCA1 or BRCA2 mutations.2, 3 In our previous
… cancer risk of 51% associated with tamoxifen use, but the observed protective effect was …

… and the potential benefit described here, and elsewhere [5], we believe that a randomized
trial of 1 year of tamoxifen versus placebo in BRCA1 and BRCA2 mutation carriers is feasible. …

… It is therefore important to evaluate the relationship between tamoxifen use … tamoxifen use
and breast cancer incidence in a large international cohort of BRCA1 and BRCA2 mutation …

… Based on these invasive breast cancer cases, we estimate RRs for breast cancer among
women with BRCA1 or BRCA2 mutations associated with use of tamoxifen vs placebo. …

… The largest, comprising data from 2464 mutation carriers, showed that tamoxifen use
after a first breast cancer was associated with a reduced risk of contralateral breast cancer [Citation…

… arises as to whether tamoxifen use, if not appropriate as … benefits of tamoxifen for BRCA1
and BRCA2 mutation carriers … of physicians toward tamoxifen use among mutation carriers. Our …

… Purpose: The purpose of this study was to assess womenÕs knowledge about tamoxifen,
to examine the frequency of tamoxifen usage and other preventive measures in BRCA1/2 …

… , hazard ratios) and the 95 % CIs for tamoxifen use and the risk of CBC in BRCA1 or BRCA2
… is suggested that tamoxifen could be used for BRCA1 or BRCA2 mutation carriers who have …